Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Trazimera [legacy through FY23] by Quarter
Trazimera (trastuzumab biosimilar) [legacy through FY23] — Worldwide reported YoY (%) (%)
Pfizer Trazimera [legacy through FY23]: -56.0% in Q4 2023, down 37.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
“|| Trazimera | 23 | 54 | (56%) | (53%) | (8) | 21 | * | 32 | 33 | (5%) | 1%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Trazimera [legacy through FY23] (%), quarterly Q4 2021–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/trazimera-leg-yoy-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.